Fisher Asset Management LLC Sells 3,851 Shares of IQVIA Holdings Inc. $IQV

Fisher Asset Management LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 43.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,099 shares of the medical research company’s stock after selling 3,851 shares during the period. Fisher Asset Management LLC’s holdings in IQVIA were worth $969,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Physician Wealth Advisors Inc. boosted its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. increased its position in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Atlantic Union Bankshares Corp bought a new position in IQVIA in the 3rd quarter worth approximately $36,000. Asset Dedication LLC lifted its holdings in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after buying an additional 168 shares during the last quarter. Finally, Rothschild Investment LLC boosted its position in shares of IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. TD Cowen boosted their target price on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. UBS Group reduced their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Evercore reaffirmed an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a research report on Thursday, February 5th. Finally, Jefferies Financial Group reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $231.13.

IQVIA Stock Down 2.2%

Shares of IQV stock opened at $174.56 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a fifty day moving average price of $207.22 and a 200 day moving average price of $207.47. The stock has a market cap of $29.62 billion, a P/E ratio of 22.21, a price-to-earnings-growth ratio of 1.68 and a beta of 1.39.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.